Insider Selling: BeOne Medicines (NASDAQ:ONC) COO Sells 6,009 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 6,009 shares of the company’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $380.54, for a total transaction of $2,286,664.86. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Xiaobin Wu also recently made the following trade(s):

• On Wednesday, November 12th, Xiaobin Wu sold 10,000 shares of BeOne Medicines stock. The stock was sold at an average price of $356.02, for a total transaction of $3,560,200.00.

BeOne Medicines Stock Performance

Shares of ONC traded down $2.54 during mid-day trading on Friday, hitting $365.82. 230,040 shares of the company traded hands, compared to its average volume of 390,826. The stock has a market cap of $40.12 billion, a price-to-earnings ratio of 717.29 and a beta of 0.31. The stock has a 50-day moving average price of $329.42 and a two-hundred day moving average price of $290.65. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $170.99 and a 1 year high of $381.50. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Qtron Investments LLC raised its stake in BeOne Medicines by 12.4% during the 3rd quarter. Qtron Investments LLC now owns 3,742 shares of the company’s stock worth $1,275,000 after acquiring an additional 412 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of BeOne Medicines in the third quarter worth $1,052,000. Tower Research Capital LLC TRC raised its position in shares of BeOne Medicines by 226.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 11,435 shares of the company’s stock valued at $3,896,000 after purchasing an additional 7,932 shares during the period. Vident Advisory LLC purchased a new position in shares of BeOne Medicines during the 3rd quarter valued at $581,000. Finally, Caption Management LLC bought a new position in BeOne Medicines in the 3rd quarter worth $1,090,000. 48.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Citigroup increased their price target on BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a report on Monday. Barclays began coverage on BeOne Medicines in a research report on Thursday, September 18th. They set an “overweight” rating and a $385.00 price objective for the company. Royal Bank Of Canada raised their target price on BeOne Medicines from $374.00 to $395.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Morgan Stanley raised their target price on BeOne Medicines from $350.00 to $383.00 and gave the stock an “overweight” rating in a research report on Monday, October 20th. Finally, Citizens Jmp upped their price target on shares of BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $357.33.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.